cbdMD Inc - Asset Resilience Ratio

Latest as of September 2023: 0.00%

cbdMD Inc (YCBD) has an Asset Resilience Ratio of 0.00% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$16.20 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2017–2023)

This chart shows how cbdMD Inc's Asset Resilience Ratio has changed over time. Check cbdMD Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down cbdMD Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see cbdMD Inc stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: cbdMD Inc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

cbdMD Inc Industry Peers by Asset Resilience Ratio

Compare cbdMD Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Alkem Laboratories Limited
NSE:ALKEM
Drug Manufacturers - Specialty & Generic 31.91%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Alkermes plc
F:8AK
Drug Manufacturers - Specialty & Generic 3.76%
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
Drug Manufacturers - Specialty & Generic 4.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131
Drug Manufacturers - Specialty & Generic 1.37%
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436
Drug Manufacturers - Specialty & Generic -2.56%

Annual Asset Resilience Ratio for cbdMD Inc (2017–2023)

The table below shows the annual Asset Resilience Ratio data for cbdMD Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-09-30 0.00% $0.00 $16.20 Million --
2022-09-30 2.45% $1.00 Million $40.79 Million +1.62pp
2021-09-30 0.83% $1.03 Million $124.88 Million +0.58pp
2020-09-30 0.25% $276.47K $110.84 Million -0.60pp
2019-09-30 0.84% $798.54K $94.52 Million -13.87pp
2018-09-30 14.72% $2.21 Million $15.02 Million +2.56pp
2017-09-30 12.15% $859.11K $7.07 Million --
pp = percentage points

About cbdMD Inc

NYSE MKT:YCBD USA Drug Manufacturers - Specialty & Generic
Market Cap
$6.78 Million
Market Cap Rank
#28019 Global
#5684 in USA
Share Price
$0.76
Change (1 day)
-2.31%
52-Week Range
$0.47 - $2.27
All Time High
$304.65
About

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products in the United States. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, ready to drink cans, and sleep, focus, and calming aids. It also provides veterinarian-formulated p… Read more